Erratum to “Pharmaceutical and clinical development of phosphonate-based radiopharmaceuticals for the targeted treatment of bone metastases” [Bone 91 (2016) 159–179](S8756328216302137)(10.1016/j.bone.2016.08.002)

The publisher regrets the references 9 through 15 were missing. They are: [9] K. Liepe, J. Kotzerke, Internal radiotherapy of painful bone metastases, Methods 55 (2011) 258–270, http://dx.doi.org/10.1016/j.ymeth.2011.07.001. [10] G. Rubini, A. Nicoletti, D. Rubini, A.N. Asabella, Radiometabolic treatment of bone-metastasizing cancer: from 186rhenium to 223radium, Cancer Biother. Radiopharm. 29 (2014) 1–11, http://dx.doi.org/10.1089/cbr.2013.1549. [11] R.G.G. Russell, Bisphosphonates: the first 40 years, Bone 49 (2011) 2–19, http://dx.doi.org/10.1016/j.bone.2011.04.022. [12] F.H. Ebetino, A.-M.L. Hogan, S. Sun, M.K. Tsoumpra, X. Duan, J.T. Triffitt, et al., The relationship between the chemistry and biological activity of the bisphosphonates, Bone 49 (2011) 20–33, http://dx.doi.org/10.1016/j.bone.2011.03.774. [13] M.J. Rogers, J.C. Crockett, F.P. Coxon, J. Monkkonen, Biochemical and molecular mechanisms of action of bisphosphonates, Bone 49 (2011) 34–41, http://dx.doi.org/10.1016/j.bone.2010.11.008. [14] F. Hosain, R.P. Spencer, Radiopharmaceuticals for palliation of metastatic osseous lesions: biologic and physical background, Semin. Nucl. Med. 22 (1992) 11–16. [15] E. van Beek, M. Hoekstra, M. van de Ruit, C. Lowik, S. Papapoulos, Structural requirements for bisphosphonate actions in vitro, J. Bone Miner. Res. 9 (1994) 1875–1882, http://dx.doi.org/10.1002/jbmr.5650091206. The publisher would like to apologize for any inconvenience caused.